Phase III Eribulin Trial Boosts OS in Liposarcoma Patients

An overlooked immune cell population may offer new direction for cell and gene therapy

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more

Efti + radiotherapy + Keytruda regimen meets primary endpoint in phase II study in soft tissue sarcoma

Investigator-initiated EFTISARC-NEO phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus Keytruda (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint.

May 30, 2025

Vol.51 No.21

Clinical Roundup

Wistar scientists uncover new viral mechanism for evading immunity, identifying a new drug target

Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram mitochondrial structure to silence immune responses and ensure successful viral reproduction.

May 23, 2025

Vol.51 No.20

Clinical

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care

For a year before an osteosarcoma was found in her right proximal tibia, Sammy Ulloa, pushing through pain, persisted with her training as a Division I track and field and cross-country competitor.

April 11, 2025

Vol.51 No.14

By Claire Marie Porter

Clinical Roundup

Keytruda improves outcomes in soft tissue sarcoma

Addition of the immunotherapy drug pembrolizumab (Keytruda) to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre.

November 15, 2024

Vol.50 No.43

Clinical Roundup

UCLA investigators develop collection of sarcoma patient-derived organoids for personalized cancer treatments

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient.

September 27, 2024

Vol.50 No.36

Phase III Eribulin Trial Boosts OS in Liposarcoma Patients

YOU MAY BE INTERESTED IN

An overlooked immune cell population may offer new direction for cell and gene therapy

Efti + radiotherapy + Keytruda regimen meets primary endpoint in phase II study in soft tissue sarcoma

Wistar scientists uncover new viral mechanism for evading immunity, identifying a new drug target

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care

Keytruda improves outcomes in soft tissue sarcoma

UCLA investigators develop collection of sarcoma patient-derived organoids for personalized cancer treatments

Renew today!

Subscriber content

Never miss an issue!

Login

Phase III Eribulin Trial Boosts OS in Liposarcoma Patients

YOU MAY BE INTERESTED IN

An overlooked immune cell population may offer new direction for cell and gene therapy

Efti + radiotherapy + Keytruda regimen meets primary endpoint in phase II study in soft tissue sarcoma

Wistar scientists uncover new viral mechanism for evading immunity, identifying a new drug target

Only half of adolescents and young adults with cancer get fertility counseling before treatmentOncofertility consult is an oft-overlooked standard of care

Keytruda improves outcomes in soft tissue sarcoma

UCLA investigators develop collection of sarcoma patient-derived organoids for personalized cancer treatments

Never miss an issue!

Login

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care